An Open-label, Single Dose, Oral Administration, Sequential Two Parts Study to Compare the Pharmacokinetics of SCH 420814 / MK-3814 in Subjects With Mild and Moderate Chronic Hepatic Impairment With Their Respectively Matching Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Preladenant (Primary)
- Indications Drug-induced dyskinesia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 27 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 27 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2012 Planned End Date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov record.